Levodopa Response Mechanisms in Parkinson's Disease

Levodopa remains the most effective symptomatic therapy for Parkinson’s disease, acting as the biochemical precursor to dopamine to restore striatal neurotransmission. Following oral administration, levodopa is absorbed in the proximal small intestine and competes with dietary amino acids for transport across the intestinal mucosa and the blood–brain barrier. Once in the central nervous system, it is decarboxylated by aromatic l-amino acid decarboxylase to dopamine, modulating motor circuits in the basal ganglia. The clinical response is influenced by pharmacokinetic factors such as formulation, gastric emptying rate and peripheral metabolism, and pharmacodynamic factors including receptor sensitivity, downstream signalling pathways and non-dopaminergic neurotransmitter systems. Interpatient variability arises from genetic polymorphisms in transporters and metabolic enzymes, differences in gut microbiota that may alter levodopa bioavailability, and synaptic plasticity within motor networks. Advances in neuroimaging have revealed network-level correlates of responsiveness, while emerging data suggest roles for immune and angiogenic pathways in modulating therapeutic outcomes. Understanding these interwoven mechanisms is crucial for optimising levodopa dosing, developing adjunctive therapies to prolong efficacy and minimising motor fluctuations and dyskinesias over the disease course.

Research from Nature Portfolio

Recent multidimensional analyses have combined genomic, transcriptomic and neuroimaging data to characterise individualised therapeutic needs in Parkinson’s disease. By applying multivariate statistics to longitudinal brain scans and blood-derived molecular profiles, researchers have identified gene expression signatures and genomic variants that explain variability in dopaminergic treatment response. These determinants overlap with established pathways such as Wnt signalling, angiogenesis and dopaminergic activity, as well as emerging immune and hormonal regulators. The strong correspondence between baseline transcriptomic markers and genetic predispositions underscores the dynamic role of the genome at treatment initiation. This integrative strategy paves the way for personalised levodopa regimens and highlights novel molecular targets to enhance clinical benefit and mitigate adverse effects.

Levodopa Response Mechanisms in Parkinson's Disease publication trend

The graph below shows the total number of articles in levodopa response mechanisms in parkinson's disease across all publications each year (not limited to Nature Index journals).

Technical terms

Levodopa: A biochemical precursor of dopamine and the primary pharmacological therapy for Parkinson’s disease.

Dopamine: A neurotransmitter critical for motor control, reward processing and modulation of basal ganglia circuits.

Pharmacokinetics: The study of absorption, distribution, metabolism and excretion of a drug.

Pharmacodynamics: The biochemical and physiological effects of a drug and its mechanisms of action.

Unified Parkinson’s Disease Rating Scale (UPDRS-III): A clinician-administered scale for assessing the severity of motor symptoms in Parkinson’s disease.

Blood–brain barrier: A selective endothelial barrier that regulates the passage of substances from the bloodstream into the central nervous system.

Transcriptomics: The analysis of complete sets of RNA transcripts to assess gene expression patterns.

Gut microbiome: The complex community of microorganisms in the gastrointestinal tract that can influence drug metabolism and host physiology.

References

1. Morphologic brain network predicts levodopa responsiveness in Parkinson disease. Frontiers in Aging Neuroscience (2023).
2. Association between Fecal Bile Acids and Levodopa Response in Patients with Parkinson’s Disease. Microorganisms (2024).
3. Putaminal y‐Aminobutyric Acid Modulates Motor Response to Dopaminergic Therapy in Parkinson's Disease. Movement Disorders (2021).
4. Multivariate genomic and transcriptomic determinants of imaging-derived personalized therapeutic needs in Parkinson’s disease. Scientific Reports (2022).